HIV Market To Meet Patent Cliff In 2026-27 But Novel Products Coming
Two-Drug Regimens Make Headway
Executive Summary
Market Snapshot: Gilead’s Biktarvy and ViiV’s two-drug regimens are expected to dominate the HIV market over the next few years as market exclusivity losses loom, but drugs with new mechanisms of action, and longer-acting products, might influence market dynamics.
You may also be interested in...
‘We Have A Lot Of Work To Do,’ Says Head Of HIV + Hepatitis Policy Institute
Progress in reducing HIV infections has plateaued in the US. But with bipartisan support, federal funding and momentum in drug development there is reason for optimism, says HIV + Hepatitis Policy Institute executive director Carl Schmid.
Merck & Co./Gilead Team To Take On ViiV In Long-Term HIV Treatment
The companies hope the combination of islatravir and lenacapavir will result in best-in-class oral and injectable long-term HIV products. A PrEP combo is a longer-term goal.
Pipeline Watch: Phase III Starts In Myelofibrosis, Birch Allergy, Non-Hodgkin's Lymphoma
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.